Related Experiment Video

Updated: Dec 5, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.8K

Effects of High-Dose Rosuvastatin on Ventricular Remodelling and Cardiac Function in ST-Segment Elevation Myocardial

Rong Luo1, Xiaochen Sun1, Feiyan Shen1

  • 1Department of Cardiology, Qingpu Medical Center, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.

Drug Design, Development and Therapy
|October 16, 2020
PubMed

Insights

High-dose rosuvastatin significantly improved cardiac function and reduced ventricular remodelling in ST-segment elevation myocardial infarction (STEMI) patients. This high-dose therapy demonstrated superior efficacy over conventional doses in lipid management and inflammatory response reduction.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • ST-segment elevation myocardial infarction (STEMI) is a critical condition characterized by myocardial damage and subsequent ventricular remodelling.
  • Statins, including rosuvastatin, are crucial for managing dyslipidemia post-MI, but optimal dosing for preventing adverse remodelling remains under investigation.

Purpose of the Study:

  • To evaluate the impact of high-dose rosuvastatin (20 mg/d) compared to conventional-dose (10 mg/d) on ventricular remodelling and cardiac function in STEMI patients.
  • To assess the effects of different rosuvastatin doses on blood lipid profiles and inflammatory markers.

Main Methods:

  • A prospective study involving 93 STEMI patients treated with either conventional (10 mg/d) or high-dose (20 mg/d) rosuvastatin for 8 weeks.
  • Measurements included blood lipids (TC, TG, LDL-C, HDL-C), inflammatory markers (hs-CRP, IL-6, TNF-α, ICAM-1), ventricular remodelling markers (NT-pro BNP, MMP-9, TIMP-4, Gal-3), and cardiac function indicators (LVESD, LVESV, LVEDV, IVST, LVEF).

Main Results:

  • High-dose rosuvastatin significantly reduced TC, TG, LDL-C, hs-CRP, IL-6, TNF-α, ICAM-1, NT-pro BNP, MMP-9, and Gal-3 levels compared to the conventional dose.
  • HDL-C and TIMP-4 levels increased more significantly with high-dose rosuvastatin.
  • High-dose rosuvastatin led to a greater improvement in cardiac function, evidenced by significantly higher LVEF and lower LV dimensions (LVESD, LVESV, LVEDV, IVST).

Conclusions:

  • High-dose rosuvastatin is more effective than conventional-dose in improving lipid metabolism and reducing inflammation in STEMI patients.
  • High-dose rosuvastatin demonstrates superior benefits in preventing and treating ventricular remodelling and myocardial fibrosis post-STEMI.
  • The findings support a stronger therapeutic role for high-dose rosuvastatin in managing STEMI compared to conventional dosing.
Abstract

Keywords:
ST elevation myocardial infarctionblood lipidsinflammatory factormyocardial fibrosisrosuvastatinventricular remodelling

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.9K
Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure09:37

Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure

Published on: December 2, 2014

28.4K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
717
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
93